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Global Trends in CD4 Cell Count at the Start of 
Antiretroviral Therapy: Collaborative Study of Treatment 
Programs
The IeDEA and COHERE Cohort Collaborationsa
Background. Early initiation of combination antiretroviral therapy (cART), at higher CD4 cell counts, prevents disease progres-
sion and reduces sexual transmission of human immunodeficiency virus (HIV). We describe the temporal trends in CD4 cell counts 
at the start of cART in adults from low-income, lower-middle-income, upper-middle-income, and high-income countries (LICs, 
LMICs, UMICs, and HICs, respectively).
Methods. We included HIV-infected individuals aged ≥16 years who started cART between 2002 and 2015 in a clinic par-
ticipating in the International epidemiology Databases to Evaluate AIDS (IeDEA) or the Collaboration of Observational HIV 
Epidemiological Research in Europe (COHERE). Missing CD4 cell counts at the start of cART were estimated through multiple 
imputation. Weighted mixed-effect models were used to smooth trends in median CD4 cell counts.
Results. A total of 951 855 adults from 16 LICs, 11 LMICs, 9 UMICs, and 19 HICs were included. Overall, the modeled me-
dian CD4 cell count at the start of cART increased from 2002 to 2015, from 78/µL (95% confidence interval, 58–104/µL) to 287/µL 
(250–328/µL) in LICs, from 99/µL (71–140/µL) to 234/µL (192–285/µL) in LMICs, from 71/µL (49–104/µL) to 311/µL (255–379/
µL) in UMICs, and from 161/µL (143–181/µL) to 327/µL (286–372/µL) in HICs. In LICs, LMICs, and UMICs, the increase was more 
pronounced in women; in HICs, the opposite was observed.
Conclusions. Median CD4 cell counts at the start of cART increased in all income groups, but generally remained below 350/μL 
in 2015. Substantial additional efforts and resources are required to achieve earlier diagnosis, linkage to care, and initiation of cART.
Keywords. antiretroviral therapy; CD4 cell count; WHO guidelines.
 
Modeling by the Joint United Nations Programme on HIV/
AIDS (UNAIDS) indicates that there is a window of oppor-
tunity to end the human immunodeficiency virus (HIV)/
AIDS epidemic by reaching the “90-90-90” targets, meaning 
that 90% of HIV infections are diagnosed, 90% of persons 
known to be HIV infected are receiving combination anti-
retroviral therapy (cART), and 90% of individuals receiving 
cART are virologically suppressed [1, 2]. In response, the 
World Health Organization (WHO) in its consolidated 2016 
guidelines on the use of antiretroviral drugs for treating and 
preventing HIV infection recommended “lifelong cART to 
all children, adolescents and adults, including all pregnant 
and breastfeeding women living with HIV, regardless of 
CD4 cell count” [3].
Many individuals who live with HIV continue to enter care 
late. A previous analysis of cART programs and HIV cohort 
studies from low-income countries (LICs), lower-middle-in-
come countries (LMICs), upper-middle-income countries 
(UMICs), and high-income countries (HICs) showed that 
median CD4 cell counts at the start of cART increased from 
2000 to 2009 but remained below 200/µL in LICs and middle-in-
come countries (MICs) and below 300/µL in HICs [4]. Similarly, 
a study published in Morbidity and Mortality Weekly Report [5] 
found that the percentage of patients starting cART with a CD4 
cell count below 200/µL had decreased in 10 LICs and MICs but 
continued to be substantial in recent years, for example, 37% in 
Mozambique in 2014, or 34% in Haiti in 2015 [5]. A meta-anal-
ysis of African studies showed that the mean estimated CD4 cell 
count in 2012 was 309/µL at presentation to care and 140/µL at 
cART initiation [6]. Similarly, a meta-regression analysis of stud-
ies in developed countries showed only a small increase in the 
CD4 cell count at presentation from 1992 to 2011 [7].
For the present study, the International epidemiology 
Databases to Evaluate AIDS (IeDEA), a large collaboration 
of cART treatment programs and HIV cohort studies in the 
Americas, sub-Saharan Africa, and Asia-Pacific joined forces 
with the Collaboration of Observational HIV Epidemiological 
Research in Europe (COHERE) to examine global trends in 
CD4 cell counts at cART initiation.
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METHODS
Data Sources
IeDEA is a consortium structured through regional centers 
to pool clinical and epidemiological data on persons living 
with HIV and receiving cART. COHERE is a collaboration 
of European HIV cohorts. Regional cohorts of IeDEA and 
COHERE have been described in detail elsewhere [8–12]. 
Institutional review boards approved the pooling of data and 
their use in collaborative analyses.
Inclusion Criteria and Definitions
We included all individuals aged ≥16 years if they had a 
recorded cART starting date and sex, were treatment naive, and 
started therapy between 2002 and 2015. We excluded countries 
that contributed <100 patients with CD4 cell counts at therapy 
start and individual patients who started therapy in a year and 
country for which <10 CD4 cell counts were reported. cART 
was defined as ≥3 antiretroviral drugs, from 2 drug classes. 
The CD4 cell count at the start of cART was the count near-
est to the date of starting cART, within a window of 3 months 
before and 1 week after initiation of therapy. CD4 cell counts 
>5000/μL (>3 times above the upper reference range [13]) were 
considered invalid. Countries were grouped according to the 
World Bank classification of gross national income per capita 
in 2015 [14], as LICs (≤$1025), LMICs ($1026–$4035), UMICs 
($4036–$12 475), and HICs (≥$12 476). Severe immunodefi-
ciency was defined as a CD4 cell count <200/μL [15]. Regions 
were defined according to IeDEA and COHERE conventions 
[8–11, 16].
Multiple Imputation of Missing CD4 Cell Counts
We imputed square roots of CD4 cell counts using predictive 
mean matching, adjusting for country and year of cART start 
and stratifying by sex, country income group, and region. We 
generated 50 imputed data sets and combined these using 
Rubin’s rule [17].
Weighted Analysis of Temporal Trends
We aggregated data by calendar year (3–14 years, depending on 
the country), country (55 countries), and sex (2 groups), and 
we calculated the median CD4 cell count at the start of cART 
for each of the resulting data cells. We assigned a weight to each 
data cell that consisted of 2 components, which were multiplied. 
The first component corresponded to the number of observa-
tions, divided by the average number of observations in data 
cells of the same country income group (and was thus normal-
ized by country income group), and captured the precision of 
the aggregated values in each data cell. The second compo-
nent corresponded to the ratio of the number of patients who 
were newly enrolled in that cohort and year to the number of 
patients starting cART in that country and year, as estimated 
by UNAIDS [18] and was also normalized by country income 
group. 
We used weighted additive mixed models to analyze tem-
poral trends in median CD4 cell counts at the start of cART. 
The covariates sex and country income group, as well as their 
interaction, were included as fixed effects, country as a ran-
dom intercept, and yearly trends smoothed by sex and country 
income group. Similarly, we analyzed the median CD4 cell count 
according to region instead of country income group. For this 
analysis, weights were normalized by region. We also modeled 
the proportion of patients starting cART with severe immuno-
deficiency (CD4 cell count <200/µL), using generalized additive 
mixed models, and we fitted this model to other CD4 cell count 
thresholds (<50/µL, <100/µL, <350/µL, and <500/µL). We used 
the data set that included imputed CD4 cell counts. In sensitiv-
ity analyses, we fitted models to the data set consisting of com-
plete cases only. We also fitted models including only cohorts 
that contributed data each year from 2005 to 2014.
We present CD4 cell counts as observed or modeled median 
CD4 cell counts with interquartile ranges (IQRs) or 95% confi-
dence intervals (CIs). All analyses were done using R software, 
version 3.2.3 (R Core Team). The appendix gives further techni-
cal details (see Supplementary Digital Content). 
RESULTS
Descriptive Analyses
We received data from 1 472 098 patients. We excluded a total of 
520 243 patients and 22 countries who did not meet the inclu-
sion criteria. Supplementary Figure S1 (see Supplementary 
Digital Content) shows the inclusion of patients. A  total of 
951 855 individuals from 55 countries (16 LICs, 11 LMICs, 9 
UMICs, and 19 HICs) were included (Table 1 and Figure 1). Five 
countries contributed 160–499 persons; 6 countries, 500–999; 
20 countries, 1000–4999; 5 countries, 5000–9999; 12 countries, 
10 000–24 999; and 7 countries, ≥25 000. The number of indi-
viduals included in each country ranged from 160 (Malaysia) to 
350 595 (Zambia).
The percentage of women was 57% overall and ranged from 
5% in South Korea to 82% in the Democratic Republic of the 
Congo. In LICs, LMICs, and UMICs, the median (IQR) age 
of individuals starting cART was 35 (29–42) years; in HICs, 
it was 39 (32–47) years. The median year of cART initiation 
ranged from 2007 in France and Honduras to 2013 in Haiti and 
Mozambique. The median CD4 cell count at cART initiation 
ranged from 106/µL in Senegal, Thailand, and Vietnam to 275/
µL in Belgium, and it was 182/μL overall; it was 179/μL (IQR, 
85–288/μL) in LICs, 172/μL (85–279/μL) in LMICs, 141/μL 
(60–227/μL) in UMICs, and 251/μL (128–370/μL) in HICs. The 
proportion of patients starting cART with severe immunodefi-
ciency (CD4 cell count <200/µL) was 55%, ranging from 31% 
in Switzerland to 77% in Senegal; this proportion was 56% in 
LICs, 58% in LMICs, 68% in UMICs, and 38% in HICs. Tables 
1 and 2 and Supplementary Table S3 show detailed results by 
country and sex.
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Table 1. Characteristics of Persons Living With Human Immunodeficiency Virus Starting Combination Antiretroviral Therapy by World Bank Income Group 
(2015), Country, and Sex
Country by Income Status
Patients, No. Age, Median, y 
Calendar Year of cART Initiation, 
Median
Range of Data, Calendar 
YearsFemale Male Female Male Female Male
Low income
 Benin 2542 1559 33 40 2009 2008 2002–2014
 Burkina Faso 7832 3312 35 41 2008 2008 2002–2014
 Burundi 3123 1711 35 43 2012 2012 2009–2015
 Democratic Republic of the Congo 1425 303 33 41 2011 2011 2005–2014
 Guinea 640 323 32 41 2012 2012 2008–2014
 Guinea-Bissau 1941 1002 35 40 2010 2010 2007–2014
 Haiti 3422 2287 34 40 2013 2013 2003–2015
 Malawi 29 965 20 219 31 37 2011 2011 2007–2015
 Mali 3222 1800 33 41 2009 2009 2002–2014
 Mozambique 6314 2925 29 36 2013 2013 2006–2015
 Rwanda 7730 4443 32 38 2008 2008 2004–2015
 Senegal 603 407 37 43 2009 2009 2002–2014
 United Republic of Tanzania 8798 3999 36 41 2009 2009 2005–2014
 Togo 2649 1351 33 40 2009 2009 2005–2009
 Uganda 27 644 15 841 32 37 2009 2009 2003–2014
 Zimbabwe 15 652 7195 36 40 2012 2012 2004–2015
 Overall (IQR)a 123 502 68 677 33 (28–40) 38 (32–45) 2011 (2008–2013) 2010 (2008–2012) 2002–2015
Lower middle income
 Cambodia 1136 1003 33 36 2009 2009 2005–2014
 Cote d’Ivoire 14 819 7725 35 42 2008 2008 2002–2014
 Honduras 436 562 33 38 2006 2007 2002–2015
 India 2802 6100 33 36 2009 2008 2002–2014
 Kenya 72 329 33 311 33 39 2010 2010 2003–2014
 Lesotho 6870 3638 35 40 2011 2011 2005–2015
 Nigeria 14 729 7587 32 39 2008 2008 2005–2014
 Philippines 16 191 36 30 2010 2009 2008–2010
 Ukraine 570 264 29 34 2008 2009 2004–2014
 Vietnam 554 918 30 34 2012 2012 2004–2014
 Zambia 217 525 133 070 33 37 2011 2011 2003–2015
 Overall (IQR)a 331 786 194 369 33 (28–40) 38 (32–44) 2010 (2008–2013) 2010 (2007–2013) 2002–2015
Upper middle income
 Argentina 888 2161 35 37 2008 2009 2002–2015
 Belarus 235 258 32 34 2009 2008 2006–2013
 Brazil 774 1941 38 35 2010 2010 2002–2015
 Malaysia 31 129 37 37 2008 2009 2004–2010
 Mexico 104 858 35 33 2009 2009 2002–2015
 Peru 872 2328 34 33 2010 2011 2004–2015
 Russian Federation 159 159 29 32 2008 2008 2003–2012
 South Africa 45 359 24 240 33 38 2010 2010 2003–2015
 Thailand 451 586 36 37 2008 2008 2003–2010
 Overall (IQR)a 48 873 32 660 33 (28–40) 37 (32–44) 2010 (2007–2012) 2010 (2007–2012) 2002–2015
High income
 Austria 627 1774 33 38 2008 2010 2002–2014
 Belgium 1205 1303 31 39 2007 2010 2002–2014
 Canada 295 818 36 39 2008 2009 2003–2013
 Chile 160 1415 37 35 2006 2009 2002–2014
 Denmark 609 1313 35 42 2007 2008 2002–2013
 France 9036 18 094 35 40 2006 2007 2002–2014
 Germany 2709 10 686 34 40 2008 2009 2002–2015
 Greece 555 2997 36 36 2008 2010 2002–2014
 Hong Kong 133 574 36 41 2009 2010 2003–2013
 Italy 3631 10 627 37 40 2009 2009 2002–2015
 Republic of Korea 18 364 41 37 2011 2010 2002–2015
 Netherlands 2806 11 078 33 41 2008 2009 2002–2015
 Poland 142 427 31 33 2007 2008 2002–2013
 Singapore 117 1643 41 42 2010 2010 2006–2014
 Spain 2218 9006 36 37 2008 2009 2002–2014
 Sweden 2138 3095 33 41 2009 2009 2002–2015
 Switzerland 882 2881 36 40 2008 2009 2002–2014
 United Kingdom 5823 13 976 35 38 2007 2008 2002–2013
 United States 4187 22 626 42 44 2008 2008 2003–2014
 Overall (IQR)a 37 291 114 697 35 (29–43) 40 (33–48) 2007 (2005–2010) 2008 (2006–2011) 2002–2015
Abbreviations: IQR, interquartile range.
aIQRs provided for median values.
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Multiple Imputation of Missing CD4 Cell Counts
The CD4 cell count measurement at the start of cART was missing in 
311 647 patients, in 44% of individuals in LICs, 33% in LMICs, 27% 
in UMICs, and 22% in HICs (Table 2). Compared with them, the 
640 208 individuals who had a CD4 cell count reported at the start 
of cART were more likely to be female and less likely to be from a 
LIC (Supplementary Table S1). Five countries from Southern Africa 
provided information about the WHO stage of patients at cART ini-
tiation. The WHO stage distributions were similar overall in patients 
with and those without reported CD4 cell counts (Supplementary 
Table S2).
Medians of imputed CD4 cell counts from the main ana-
lysis and the complete cases (sensitivity analysis) were similar 
(Table  2 and Supplementary Table S3). Differences in CD4 
cell counts ranged from −10/μL in Ukraine to +10.5/μL in 
Burundi. Similarly, the proportion of patients starting cART 
with counts <200/μL were similar for imputed and complete 
data. The differences ranged from −4.7% in Togo to +3.4% in 
Ukraine.
Temporal Trends in CD4 Cell Counts
The estimated median CD4 cell count at the start of cART from 
2002 to 2015 varied across income groups (Figure 2). The mod-
eled median CD4 cell count at cART initiation increased in LICs 
by 268%, from 78/µL (95% CI, 58–104/µL) to 287/µL (250–328/
µL); in LMICs by 136%, from 99/µL (71–140/µL) to 234/µL 
Figure 1. Map of countries contributing patients to the collaborative analysis by number of patients (A) and country income group (B).
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(192–285/µL); in UMICs by 338%, from 71/µL (49–104/µL) 
to 311/µL (255–379/µL); and in HICs by 103%, from 161/µL 
(143–181/µL) to 327/µL (286–372/µL). In LICs, LMICs, and 
UMICs the increase was more pronounced in women (+277% 
in LICs, +153% in LMICs, and +391% in UMICs) than in men 
(+248% in LICs, +99% in LMICs, and +261% in UMICs); in 
HICs the opposite was the case (+68% in women and +115% 
in men). Results of the complete case analysis and analysis 
restricted to cohorts contributing data from 2005–2014 were 
similar (Supplementary Figure S2A and S2B, Supplementary 
Digital Content).
Figure 3 shows modeled temporal trends in the proportion of 
patients starting cART with severe immunodeficiency (CD4 cell 
count <200/µL) and below other thresholds. In LICs, the estimated 
proportion of adults starting with severe immunodeficiency 
declined from 95% (95% CI, 90%–97%) in 2002 to 31% (26%–
36%) in 2015. Corresponding declines were from 75% (95% CI, 
65%–83%) to 40% (33%–47%) in LMICs, from 79% (71%–86%) 
to 26% (20%–33%) in UMICs, and from 59% (54%–64%) to 29% 
(24%–34%) in HICs. For the lowest 3 CD4 thresholds (<50/µL, 
<100/µL, and <200/µL) the proportions of patients starting cART 
below the threshold declined over the study-period. However, 
trends plateaued toward the end of the study period, for example, 
for individuals from HICs or LMICs who started therapy with 
CD4 cell counts below 100/µL or 200/µL. The proportions for the 
2 highest CD4 thresholds (<350/µL and <500/µL) were constant 
over the first few years and then started to decrease. Results of the 
complete case analysis and analysis restricted to cohorts contrib-
uting data from 2005–2014 were similar (see Figure S3A and S3B, 
Supplementary Digital Content).
Supplementary Figure S4 shows the modeled temporal 
trends in median CD4 cell count at the start of cART by sex 
and region. Regions showed different trends, with the largest 
increases in median CD4 cell count at the start of cART from 
2003 to 2014 seen in Southern Africa (from 93/µL [95% CI, 
60–146/µL] to 259/µL [224–300/µL]) and North America (from 
172/µL [131–227/µL] to 435/µL [317–597/µL]) and the smallest 
increases seen in West Africa (from 118/µL [88–158/µL] to 186/
µL [160–217/µL]) and East Europe (from 160/µL [101–254/
µL] to 261/µL [199–342/µL]). Results from complete case ana-
lysis and analysis restricted to cohorts contributing data from 
2005–2014 were similar (see Supplementary Figure S4A and 
S4B, Supplementary Digital Content).
DISCUSSION
This global analysis of the CD4 cell count at cART initiation 
included almost 1 million individuals living with HIV in North 
America, Latin America and the Caribbean, Asia-Pacific, 
sub-Saharan Africa, and Europe. The median CD4 cell count 
substantially increased in all 4 groups of countries defined by 
per capita income, with steeper increases in LICs and UMICs 
than in LMICs or HICs. In 2015, these counts were highest in 
HICs, followed by UMICs, LICs, and LMICs. There were also 
important differences between regions. For example, the esti-
mated median CD4 cell count in individuals starting cART in 
North America rose to 435/µL in 2014; at the other end of the 
spectrum, it was 186/µL in individuals starting cART in West 
Africa in the same year. Median CD4 cell counts were higher 
and increases steeper in women than in men, except in HICs, 
where in recent years women started cART with lower counts 
than men. The proportion starting therapy with severe im-
munodeficiency decreased substantially, but trends seemed to 
have plateaued in recent years, especially in HICs.
The decreases in the proportion of patients starting therapy 
below the different CD4 thresholds mirror the WHO guide-
lines to some extent. For example, the proportion starting with 
Figure 2. Median CD4 cell count in adults at the start of combination antiretroviral therapy (cART) by sex and country income group. Results from additive mixed-effects 
model based on 951 855 adults after imputation of missing data. 95% confidence intervals are shown as shaded areas.
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a CD4 cell count below 350/µL was close to 100% in LICs, 
LMICs, and UMICs until about 2010, and started declining 
after that point, possibly owing to the implementation of the 
2009 guideline [19]. In HICs the decline had already started 
before the guideline expansion, in 2008. This reflects the fact 
that national guidelines in resource-limited settings generally 
echoed WHO guidelines [20], whereas HICs have more rapidly 
increased the CD4 cell count threshold for initiation of cART. 
For example, in 2012 North American guidelines converged in 
their recommendation that cART should be offered to all HIV-
infected individuals, irrespective of CD4 cell count [21, 22]. The 
WHO followed suit in 2016, recommending “lifelong cART for 
all children, adolescents and adults, including all pregnant and 
breastfeeding women living with HIV, regardless of CD4 cell 
count” [3]. The impact of these recommendations will be the 
subject of future collaborative analyses.
Figure 3. Proportion of patients starting combination antiretroviral therapy (cART) with CD4 cell counts below 50/µL, 100/µL, 200/µL, 350/µL, and 500/µL (rows) by sex 
(columns) and country income group (colors). Results from generalized additive mixed effects models based on 951 855 adults after imputation of missing data. 95% confi-
dence intervals are shown as shaded areas.
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It is likely that the substantial rise in HIV testing in many 
countries, supported by governments, the US President’s 
Emergency Plan for AIDS Relief (PEPFAR), the Global Fund, 
and other donors contributed to increasing CD4 cell counts 
at the start of cART [23], but this may not have been the case 
in all settings [24, 25]. The steeper increase in CD4 cell count 
among women compared with men in LICs and MICs may be 
explained by increased testing coverage after scale-up of pro-
grams to prevent mother-to-child transmission. UNAIDS esti-
mates that 90% of pregnant women living with HIV in Eastern 
and Southern Africa, 48% in Central and West Africa and 41% 
in Asia and the Pacific received antiretroviral drugs [26], up 
from <5% in 2002 [27]. However, among the 22 UNAIDS pri-
ority countries [28], several still had coverage rates below 50% 
in 2015 for programs to prevent mother-to-child transmission, 
including India, Chad and Nigeria [26].
Analyses were based on raw data from many HIV-infected 
individuals starting cART, which is an important strength of 
this study. Such individual patient data meta-analyses have been 
described as the “yardsticks” against which the quality of other 
reviews should be judged [29]. Our results are consistent with 
an earlier analysis of IeDEA and European data, based on indi-
vidual patient data from 379 865 patients in 23 countries, which 
showed that CD4 cell counts in LICs and MICs increased from 
about 90/µL in 2002 to about 150/µL in 2009 [4]. Our results 
are also in line with analyses of individual patient data from a 
smaller number of countries [5, 30, 31].
The weighting of estimates was another strength, with more 
weight given to the more precise estimates of median CD4 cell 
count, and by the number of patients starting cART in a given 
country and year [18], so that countries with many patients 
starting cART were adequately represented in our analysis. 
Our study also had several limitations. We included data up to 
2015, but not all countries contributed data spanning the entire 
period from 2002 to 2015. It is reassuring that results were very 
similar when we restricted analyses to the cohorts that contrib-
uted data for each year from 2005 to 2014. 
Another limitation was that many individuals had miss-
ing CD4 cell counts at cART initiation, which we addressed 
by multiple imputation. Results including the imputed values 
were very similar to those of complete case analyses. If some of 
the CD4 cell counts were missing owing to poorer health, this 
would violate the assumption of values missing at random and 
lead to overestimation of the median count. For example, some 
patients with missing CD4 cell counts may have started therapy 
immediately because of an opportunistic infection and might 
thus be more likely to have a lower count, especially in LICs. 
Data on opportunistic infections and clinical stage was incom-
plete, and we could not use this information in our imputation 
models. However, for the 5 Southern African countries, which 
provided information on clinical stage, the WHO stage distri-
bution overall was similar in patients with reported and those 
with missing CD4 cell counts. These data indicate that, at least 
in Southern Africa, only a small portion of missing counts are 
due to poorer health.
Data from some countries were limited to a small number 
of patients from a single clinic. We excluded these data sets be-
cause the data were probably unrepresentative of all patients 
receiving cART in those countries. Some data included in mod-
eling of time trends may also not be representative of all patients 
receiving cART in the country. In particular, the clinics from 
LICs and MICs participating in IeDEA are mainly urban and 
capture data in electronic databases, indicating a higher level of 
resources. They may more closely reflect best practice in urban 
settings than in the country as a whole [8]. Nevertheless, our 
collaborative study is a unique source of information on trends 
and determinants of the CD4 cell count in adult patients start-
ing cART across the globe.
In conclusion, median CD4 cell counts at the start of cART 
have increased in all country income groups over the last few 
years, and the proportion of individuals starting cART with se-
vere immunodeficiency has decreased. However, the median 
CD4 cell count at cART start generally remained below 350/μL 
in 2015 and the decline in severe immunodeficiency appears to 
have plateaued in some countries. Clearly, substantial additional 
efforts and resources will be needed to achieve early diagnosis, 
rapid linkage to care, and prompt initiation of cART globally.
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